AI-driven Clairity Breast platform, now FDA-approved, predicts five-year breast cancer risk from mammograms, enhancing early ...

qXR-LN is an FDA-cleared solution to assist physicians with early nodule detection. Studies have shown that AI is highly ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

In a large Norwegian study, a commercial AI tool analyzed routine mammograms and identified women at elevated risk of ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new ...

Under the partnership, GE HealthCare will serve as the technology partner, and TMC will be the clinical oncology partner.

Tata Memorial Centre partners with GE HealthCare to advance cancer care in India with AI-driven solutions and innovative ...

Tata Memorial Centre collaborates with GE HealthCare to establish a cutting-edge Cancer Research & Innovation Centre aimed at ...

With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...

Seer Inc. (NASDAQ:SEER) announced a significant population-level study in collaboration with Korea University.